Interim results of a pilot study demonstrating the early effects of the PPAR-gamma ligand rosiglitazone on insulin sensitivity, aminotransferases, hepatic steatosis and body weight in patients with non-alcoholic steatohepatitis.

@article{NeuschwanderTetri2003InterimRO,
  title={Interim results of a pilot study demonstrating the early effects of the PPAR-gamma ligand rosiglitazone on insulin sensitivity, aminotransferases, hepatic steatosis and body weight in patients with non-alcoholic steatohepatitis.},
  author={Brent A Neuschwander-Tetri and Elizabeth M. Brunt and Kent R. Wehmeier and Craig A Sponseller and Karen Hampton and Bruce R. Bacon},
  journal={Journal of hepatology},
  year={2003},
  volume={38 4},
  pages={434-40}
}
BACKGROUND/AIMS Hyperinsulinemia may cause hepatic steatosis and non-alcoholic steatohepatitis (NASH). The aims of this pilot study were to examine the safety of using the insulin-sensitizing peroxisomal proliferator activated receptor (PPAR) gamma ligand rosiglitazone in patients with NASH and determine whether improved insulin sensitivity correlates with improved fatty liver. METHODS Thirty subjects with NASH and elevated alanine aminotransferase (ALT) levels received rosiglitazone, 4 mg… CONTINUE READING